Eliem Therapeutics (ELYM) Competitors $1.90 +0.18 (+10.47%) As of 08/15/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock ELYM vs. TRDA, EPRX, IPHA, NLTX, VTYX, ENGN, EDIT, VYGR, GNFT, and SXTCShould you be buying Eliem Therapeutics stock or one of its competitors? The main competitors of Eliem Therapeutics include Entrada Therapeutics (TRDA), Eupraxia Pharmaceuticals (EPRX), Innate Pharma (IPHA), Neoleukin Therapeutics (NLTX), Ventyx Biosciences (VTYX), enGene (ENGN), Editas Medicine (EDIT), Voyager Therapeutics (VYGR), GENFIT (GNFT), and China SXT Pharmaceuticals (SXTC). These companies are all part of the "pharmaceutical products" industry. Eliem Therapeutics vs. Its Competitors Entrada Therapeutics Eupraxia Pharmaceuticals Innate Pharma Neoleukin Therapeutics Ventyx Biosciences enGene Editas Medicine Voyager Therapeutics GENFIT China SXT Pharmaceuticals Entrada Therapeutics (NASDAQ:TRDA) and Eliem Therapeutics (NASDAQ:ELYM) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, media sentiment, earnings and risk. Is TRDA or ELYM more profitable? Eliem Therapeutics has a net margin of 0.00% compared to Entrada Therapeutics' net margin of -92.30%. Entrada Therapeutics' return on equity of -17.81% beat Eliem Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Entrada Therapeutics-92.30% -17.81% -14.55% Eliem Therapeutics N/A -47.03%-45.97% Does the media refer more to TRDA or ELYM? In the previous week, Entrada Therapeutics had 19 more articles in the media than Eliem Therapeutics. MarketBeat recorded 19 mentions for Entrada Therapeutics and 0 mentions for Eliem Therapeutics. Eliem Therapeutics' average media sentiment score of 0.00 beat Entrada Therapeutics' score of -0.28 indicating that Eliem Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Entrada Therapeutics Neutral Eliem Therapeutics Neutral Which has more volatility and risk, TRDA or ELYM? Entrada Therapeutics has a beta of -0.12, suggesting that its share price is 112% less volatile than the S&P 500. Comparatively, Eliem Therapeutics has a beta of -0.39, suggesting that its share price is 139% less volatile than the S&P 500. Do institutionals and insiders have more ownership in TRDA or ELYM? 86.4% of Entrada Therapeutics shares are owned by institutional investors. Comparatively, 69.8% of Eliem Therapeutics shares are owned by institutional investors. 8.1% of Entrada Therapeutics shares are owned by insiders. Comparatively, 4.7% of Eliem Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Which has better earnings and valuation, TRDA or ELYM? Entrada Therapeutics has higher revenue and earnings than Eliem Therapeutics. Eliem Therapeutics is trading at a lower price-to-earnings ratio than Entrada Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEntrada Therapeutics$210.78M0.95$65.63M-$1.78-2.96Eliem TherapeuticsN/AN/A-$35.12M-$0.53-3.58 Do analysts prefer TRDA or ELYM? Entrada Therapeutics currently has a consensus target price of $25.67, suggesting a potential upside of 387.03%. Given Entrada Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Entrada Therapeutics is more favorable than Eliem Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Entrada Therapeutics 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.00Eliem Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryEntrada Therapeutics beats Eliem Therapeutics on 13 of the 16 factors compared between the two stocks. Get Eliem Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ELYM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ELYM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ELYM vs. The Competition Export to ExcelMetricEliem TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$56.53M$779.54M$5.68B$9.81BDividend YieldN/A4.84%3.79%4.11%P/E Ratio-3.581.2131.0825.11Price / SalesN/A26.44466.21115.16Price / CashN/A19.5637.4059.05Price / Book0.496.599.096.18Net Income-$35.12M-$4.71M$3.26B$265.11M7 Day Performance11.76%3.22%7.36%4.21%1 Month Performance38.69%2.46%5.47%2.01%1 Year Performance-69.11%13.65%30.61%23.74% Eliem Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ELYMEliem TherapeuticsN/A$1.90+10.5%N/A-71.8%$56.53MN/A-3.589High Trading VolumeTRDAEntrada Therapeutics2.5864 of 5 stars$5.08+1.1%$25.67+405.7%-67.6%$192.98M$210.78M-2.85110EPRXEupraxia Pharmaceuticals1.9756 of 5 stars$5.37+0.7%$11.00+105.0%+104.6%$192.93MN/A-7.0629News CoveragePositive NewsEarnings ReportAnalyst RevisionIPHAInnate Pharma2.2463 of 5 stars$2.09-3.5%$11.00+427.6%-5.1%$192.20M$21.77M0.00220Short Interest ↑Gap UpNLTXNeoleukin TherapeuticsN/A$20.35-4.1%N/A-39.8%$191.25MN/A-6.5490News CoverageHigh Trading VolumeVTYXVentyx Biosciences2.7789 of 5 stars$2.68+1.3%$7.50+180.4%+47.4%$190.75MN/A-1.5930ENGNenGene3.338 of 5 stars$3.73+0.9%$23.29+525.1%-37.6%$190.35MN/A-2.2631News CoverageShort Interest ↓EDITEditas Medicine4.2814 of 5 stars$2.26+2.5%$4.70+108.4%-24.3%$188.77M$32.31M-0.74230News CoverageEarnings ReportAnalyst ForecastGap UpVYGRVoyager Therapeutics3.7126 of 5 stars$3.35+8.7%$13.25+295.8%-42.5%$185.55M$80M-1.81100GNFTGENFIT2.1663 of 5 stars$3.69-1.2%$13.00+252.8%-7.2%$184.25M$76.77M0.00120SXTCChina SXT Pharmaceuticals0.4124 of 5 stars$1.58-0.3%N/A-80.5%$183.33M$1.74M0.0090Short Interest ↑Gap Up Related Companies and Tools Related Companies Entrada Therapeutics Alternatives Eupraxia Pharmaceuticals Alternatives Innate Pharma Alternatives Neoleukin Therapeutics Alternatives Ventyx Biosciences Alternatives enGene Alternatives Editas Medicine Alternatives Voyager Therapeutics Alternatives GENFIT Alternatives China SXT Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ELYM) was last updated on 8/16/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | Sponsored"I'm risking my reputation on this"A massive supply shock is building in the crypto market that could send Bitcoin to $300,000 this year. That...Crypto 101 Media | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredBut this $20 American company could control the secretThe "Impossible" Chip That Runs on Pure Light Google's quantum computer shocked the world... but China DEMO...The Oxford Club | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eliem Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eliem Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access